Exercise Perceptions and Preferences Among Rheumatoid Arthritis Patients

This study has been completed.
Sponsor:
Collaborator:
Centre Hospitalier Universitaire and University of Lausanne
Information provided by:
University of Lausanne
ClinicalTrials.gov Identifier:
NCT01596348
First received: June 21, 2011
Last updated: May 10, 2012
Last verified: May 2012
  Purpose

The purpose of the study is to analyse exercise behaviour of rheumatoid arthritis patients.


Condition
Rheumatoid Arthritis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Perceived Exercise Benefits, Barriers and Preferences Among Swiss Rheumatoid Arthritis Patients

Resource links provided by NLM:


Further study details as provided by University of Lausanne:

Primary Outcome Measures:
  • Exercise status [ Designated as safety issue: No ]
    • Trained
    • Active
    • Irregularly active
    • Partially active
    • Inactive

  • Exercise stages of change [ Designated as safety issue: No ]

    Prochaska 1992:

    • Precontemplation
    • Contemplation
    • Preparation
    • Action
    • Maintenance

  • Perceived exercise benefits [ Designated as safety issue: No ]
    Questionnaire developped by YH based on existing qualitive studies

  • Perceived exercise barriers [ Designated as safety issue: No ]
    Questionnaire developped by Brittain et al. 2011

  • Exercise preferences [ Designated as safety issue: No ]
    Developped by YH based on previous studies


Secondary Outcome Measures:
  • Functional status [ Designated as safety issue: No ]
    Health Assessment Questionanire (Guillemin et al. 1991)

  • Pain [ Designated as safety issue: No ]
    Visual analogue scale (VAS)

  • Fatigue [ Designated as safety issue: No ]
    VAS

  • Disease activity [ Designated as safety issue: No ]
    Disease activity score 28 (DAS 28), based on the number of tender and swollen joints and the erythrocite sedimentation rate (ESR)

  • Quality of life [ Designated as safety issue: No ]
    Arthritis Impact Measurement Scales 2


Enrollment: 120
Study Start Date: June 2011
Study Completion Date: November 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
RA patients
Patients with Rheumatoid Arthritis

  Eligibility

Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients will be selected in the Rheumatology Department of the Centre Hospitalier universitaire Vaudois in Lausanne.

Criteria

Inclusion Criteria:

  • Rheumatoid arthritis
  • Age 30 to 80 years

Exclusion Criteria:

  • Language difficulties and no help from family members or friends
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01596348

Locations
Switzerland
Centre Hospitalier Universitaire Vaudois, Département de l'Appareil Locomoteur
Lausanne, Switzerland
Sponsors and Collaborators
University of Lausanne
Centre Hospitalier Universitaire and University of Lausanne
Investigators
Study Director: Alexander KL So, PhD, FRCP Université de Lausanne, Service de Rhumatologie, Département de l'Appareil Locomoteur, Lausanne, Suisse
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT01596348     History of Changes
Other Study ID Numbers: PR_Ex
Study First Received: June 21, 2011
Last Updated: May 10, 2012
Health Authority: Switzerland: Ethikkommission

Keywords provided by University of Lausanne:
Exercise
Barriers
Benefits
Preferences
Stages of change

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on July 24, 2014